Type 2 Diabetes Mellitus
Conditions
Keywords
Type 2 Diabetes Mellitus, KBP-042
Brief summary
This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II trial of twelve weeks of KBP-042 administered as daily s.c. injections in subjects with Type 2 Diabetes Mellitus with inadequate glycaemic control while treated with a stable dose of metformin. The trial is planned to be performed in Czech Republic, Denmark, Moldova, Poland, Romania and United Kingdom
Interventions
DRUGDaily injection of KBP/placebo for 12 weeks as add-on to metformin
Daily subcutaneous injection
Sponsors
Nordic Bioscience A/S
KeyBioscience AG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects, 18-75 years of age, both inclusive, at the time of the first screening visit. Women must be either using adequate, highly effective methods of contraception, be post-menopausal or be considered sterile due to tubal ligation or other surgical procedures at the time of randomization. Sexually active men with a female partner of childbearing potential must agree in the use of highly effective method of contraception by the female partner throughout the trial period. 2. Subjects with type 2 diabetes mellitus diagnosis whose HbA1c levels are ≥7.0% and ≤10.0% (53 mmol/mol to 86 mmol/mol, respectively) at screening. 3. Stable therapy (for at least 90 days prior to randomization) with metformin. 4. Body mass index (BMI) ≥ 25.0 kg/m², and ≤ 45.0 kg/m². 5. The subject is able to understand and comply with protocol requirements. 6. The subject is able and willing to give written informed consent.
Exclusion criteria
1. Investigator considering the subject inappropriate for inclusion in the study based on medical interview and/or physical examination. 2. Past or present significant co-morbidity (other than type 2 diabetes mellitus) including, but not limited to: Active liver disease (other than asymptomatic non-alcoholic fatty liver disease), significant renal disease (including creatinine clearance \< 45 ml/min by the Modification of Diet in Renal Disease (MDRD) method, congestive heart failure (NYHA class III or IV), myocardial infarction within the past 12 months, unstable angina pectoris. 3. Prior treatment in clinical trials with dual amylin and calcitonin receptor agonists (DACRAs). 4. Currently receiving medical treatment for obesity. 5. History of bariatric surgery. 6. Current alcohol abuse. 7. Current medical non-metformin anti-diabetic therapy, including SGLT2-inhibitors, DPP4-inhibitors (dipeptidyl peptidase 4 inhibitors), GLP-1 (Glucagon-like peptide 1) analogues, insulin and sulfonylureas, for a period of 90 days prior to randomization. 8. Use of thiazolidinediones (glitazones) lasting for more than one month within 90 days of randomization. 9. Regular use of insulin or insulin analogues. 10. History or presence of sensitivity or allergy to the study drug or drugs, to their components, or drugs of these classes or a history of drug or other allergy that contraindicates participation. 11. History of sarcoma or other malignancy within the past five years, except adequately treated basal cell or squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ. 12. Participation in a study trial with any investigational new drug (new chemical entity) within 90 days prior to the start of the study. 13. Pregnant females as determined by positive serum or urine human chorionic gonadotropin (hCG) test at screening or prior to randomization or during the treatment phase of the trial. 14. Breast-feeding women. 15. Known positive test results for hepatitis C antibodies, hepatitis B surface antigen, and HIV at screening. 16. ALT (alanine transaminase) or AST (aspartat transaminase) \> 2.5 times the upper limit of normal at screening or other clinically significant liver function test abnormalities. 17. Clinically significant ECG abnormalities, as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in blood HbA1c at 12 weeks versus placebo. | At 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in body weight at 12 weeks versus placebo. | At 12 weeks |
| Change from baseline in fasting serum glucose at 12 weeks versus placebo | At 12 weeks |
| Change from baseline in fasting serum insulin at 12 weeks versus placebo | At 12 weeks |
| Change from baseline in fasting serum glucagon at 12 weeks versus placebo | At 12 weeks |
| Proportion of subjects reaching a level of HbA1c below 7.0% (53 mmol/mol) at 12 weeks versus placebo | At 12 weeks |
Countries
Czechia, Denmark, Moldova, Poland, Romania, United Kingdom
Outcome results
None listed